KRYS - Krystal Biotech, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
117.85
+2.39 (+2.07%)
At close: 04:00PM EDT
120.21 +2.36 (+2.00%)
After hours: 05:04PM EDT
Stock chart is not supported by your current browser
Previous Close115.46
Open115.99
Bid0.00 x 800
Ask0.00 x 800
Day's Range115.52 - 118.81
52 Week Range49.17 - 123.84
Volume373,999
Avg. Volume268,539
Market Cap3.04B
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-5.05
Earnings DateAug 07, 2023 - Aug 11, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est135.88
  • Simply Wall St.

    Are Investors Undervaluing Krystal Biotech, Inc. (NASDAQ:KRYS) By 41%?

    Key Insights Using the 2 Stage Free Cash Flow to Equity, Krystal Biotech fair value estimate is US$206 Krystal Biotech...

  • GlobeNewswire

    Option Care Health Selected by Krystal Biotech as Part of a Limited Distribution Specialty Pharmacy Network for VYJUVEK™

    Company to Deliver to Patients FDA-Approved Topical Treatment for Dystrophic Epidermolysis Bullosa (DEB) Announces Collaboration with Amedisys to Administer Treatment in the Home BANNOCKBURN, Ill., May 23, 2023 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH) today announced that it was selected by Krystal Biotech, Inc. (“Krystal Biotech”) (Nasdaq: KRYS) as part of a limited distribution specialty pharmacy network for VYJUVEK™. VYJUVEK was approved by the U.S. F

  • Motley Fool

    Why Shares of Krystal Biotech Are Rising Monday

    Shares of Krystal Biotech (NASDAQ: KRYS) were up more than 15% Monday morning. The company announced on Friday that it had received Food and Drug Administration (FDA) approval for Vyjuvek (beremagene geperpavec-svdt) as the first therapy to treat dystrophic epidermolysis bullosa (DEB), known as "butterfly skin," at the genetic level. The rare disease weakens the skin, causes it to blister easily and leading to a greater incidence of injuries.

  • Zacks

    Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%

    Krystal's (KRYS) stock soars 10% on Friday after the company announces the FDA approval of Vyjuvek for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa.

  • GlobeNewswire

    Krystal Biotech Announces $160 Million Private Placement Equity Financing

    PITTSBURGH, May 22, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the Company) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced that it has entered into a securities purchase agreement for the sale of 1,729,729 shares of its common stock at $92.50 per share in a private placement (the PIPE) to certain qualified institutional buyers. Gross proceeds from the PIPE are expected to be approximately $

  • Reuters

    UPDATE 1-U.S. FDA approves Krystal Biotech's skin disorder gene therapy

    The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's topical gene therapy for patients with a genetic skin disorder, making it the first-of-its kind treatment for epidermolysis bullosa. The therapy, Vyjuvek, has been approved for the treatment of dystrophic epidermolysis bullosa, a rare and severe genetic disease that usually presents at birth. Patients with the disease suffer from open wounds, causing skin infections and are at an increased risk of vision loss, scarring and even lead to skin cancer that can be fatal.

  • GlobeNewswire

    Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec-svdt) for the Treatment of Dystrophic Epidermolysis Bullosa

    Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™ (beremagene geperpavec) for the Treatment of Dystrophic Epidermolysis Bullosa The rendering of the above VYJUVEK™ carton is for illustrative purposes only and is not actual product image Dystrophic Epidermolysis Bullosa (DEB) is a serious rare genetic disease that affects the skin and mucosal tissues and is caused by one or more mutations in the COL7A1 gene, resulting in lack of production of functional typ

  • Investing.com

    Weekly biotech pulse: X4 Pharma data on deck, AbbVie set for FDA review

    Investing.com -- Here is your weekly Pro Recap preview of key biotech and FDA catalysts to look out for in the next week: new data from X4 Pharma, upcoming review dates for Krystal Biotech, and a torrent of news set for release at an annual biotech conference.

  • GlobeNewswire

    Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights

    PDUFA date of May 19, 2023Presented clinical data at ARVO on topical application of B-VEC to the eye to treat ocular complications in a patient with recessive dystrophic epidermolysis bullosa under Compassionate Use ProgramStrong balance sheet, closing the quarter with $355.5 million in cash, cash equivalents and investments PITTSBURGH, May 08, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic

  • GlobeNewswire

    Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program

    Figure 1: Slit lamp pictures of the right eye. A: Baseline ankyloblepharon. The visual acuity was hand motion (HM) Figure 1: Slit lamp pictures of the right eye. B: Ocular surface of the right eye 6 months after the surgery after B-VEC applications. Data presented at Association for Research in Vision and Ophthalmology Annual Meeting on April 23, 2023Topical application of B-VEC to the eye was well tolerated and patient showed significant improvement of visual acuity and complete corneal re-epit

  • Simply Wall St.

    Krystal Biotech, Inc. (NASDAQ:KRYS): When Will It Breakeven?

    Krystal Biotech, Inc. ( NASDAQ:KRYS ) is possibly approaching a major achievement in its business, so we would like to...

  • GlobeNewswire

    Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest

    PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), today announced treatment of the first subject in the Phase 1, Cohort 3 study of KB301 for the improvement of lateral canthal lines at rest. Jeune’s lead product candidate, KB301, delivers the human COL3A1 gene to targeted skin cells that in turn produce natural type 3 collagen. Natural collagen 3 is the first in a pipeline of key skin pr

  • GlobeNewswire

    Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting

    Clinical data on the compassionate use of B-VEC to treat a RDEB patient, with recurrent cicatrizing conjunctivitis that leads to conjunctival scarring, at the Bascom Palmer Eye Institute PITTSBURGH, April 13, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will be presenting new data on the compassionate use of topica

  • GlobeNewswire

    Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

    PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors. “I am pleased to welcome Catherine to our Board of Directors at this crucial next stage of Krystal’s evolution,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. “As

  • GlobeNewswire

    Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

    PITTSBURGH, March 02, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the 43rd Annual TD Cowen Health Care Conference, which is taking place in Boston from March 6-8. Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host investor

  • GlobeNewswire

    Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

    • B-VEC PDUFA date May 19, 2023 • Data from the pivotal Phase 3 (GEM-3) trial of B-VEC for dystrophic epidermolysis bullosa published in the New England Journal of Medicine • Four pipeline clinical trials in dermatology, respiratory and aesthetics to initiate in 2023 • Strong balance sheet, closing the quarter with $383.8 million in cash, cash equivalents and investments PITTSBURGH, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), a biotechnology company f

  • Simply Wall St.

    We're Hopeful That Krystal Biotech (NASDAQ:KRYS) Will Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • GlobeNewswire

    Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis

    PITTSBURGH, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the European Commission has granted orphan designation for KB407 for the treatment of Cystic Fibrosis (CF). KB407 is an investigational, redosable gene therapy designed to correct the underlying cause of cystic fibrosis by delivering two copies of the CFTR gene

  • GlobeNewswire

    Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

    NEW PDUFA DATE OF MAY 19, 2023PITTSBURGH, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that on January 5, 2023, the U.S. Food and Drug Administration (FDA) notified the Company that based on manufacturing information submitted to the Agency on December 20, 2022, in response to an information request, the PDUFA date has been revised to May 19, 2023, and proposed labeling discussions to no later than April 20, 2023. The manufacturing inform

  • Investing.com

    BofA Securities: The most promising biotech stocks in 2023

    Investing.com - After a tumultuous year for the biotech sector, BofA Securities sees early positive signs for 2023, outlining a number of biotech stocks in new research that could see strong gains in the coming year on the back of positive trial data and a gradual return of investor risk appetite.

  • GlobeNewswire

    New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

    PITTSBURGH, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that data from the pivotal Phase 3 (GEM-3) trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa (DEB) have been published here in the New England Journal of Medicine (NEJM). The full manuscript, titled “Trial of Beremagene Geperpavec (B-VEC) fo

  • Motley Fool

    2 Risky Stocks That Could Soar in 2023

    Investing in small-cap stocks can be very risky. Let's consider two small-cap stocks that carry above-average risk but that could soar as early as next year if things work out: Bluebird Bio (NASDAQ: BLUE) and Krystal Biotech (NASDAQ: KRYS). Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses.

  • GlobeNewswire

    Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

    PITTSBURGH, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced that the company will participate in the investor-focused Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference, which is taking place in Miami on December 8. September Riharb, Senior Vice President of Marketing for Jeune, will participate in an aesthetic dermatology panel on De

  • GlobeNewswire

    Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference

    PITTSBURGH, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the BofA Securities 2022 Biotech SMID Cap Conference, which is taking place virtually from December 7-8. Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and host in

  • GlobeNewswire

    Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference

    PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the Evercore ISI 5th Annual HealthCONx Conference, which is taking place virtually from November 29-December 1. Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in a fireside chat during the conference and